NCT05529160

Brief Summary

The study is a prospective, 1-arm, open label, nonrandomized, single center study designed to evaluate label comprehension, device usability and safety of the FERTI·LILY Conception Cup. The primary safety endpoint will be an assessment of reported adverse events. Subjects will be screened -10 (±3) days prior to the baseline visit. At baseline, 15-20 subjects meeting the inclusion/exclusion criteria will be provided with a FERTI·LILY Conception Cup device and instructions for using the device. Subjects will participate in a label comprehension protocol that includes the physician confirmation that they have adequate comprehension to enroll. If not, a screen failure form is completed. Subjects will agree to try and use the device within 2 weeks of disposition therefore at baseline a two-week visit is scheduled. In the event they do not use the device within the two-week period the follow up visit can be rescheduled based on the visit window of +14 days. If it is not used within 4 weeks, the PI will have the subject return to the site to authorize another two-week period that will be captured as unscheduled follow up visit. The subject should complete the Device Experience Survey after each device use. The Device Experience Survey will be returned at this time, and adverse events will be assessed.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
18

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 29, 2022

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

September 1, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 6, 2022

Completed
14 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 20, 2022

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 21, 2022

Completed
Last Updated

April 6, 2023

Status Verified

September 1, 2022

Enrollment Period

2 months

First QC Date

September 1, 2022

Last Update Submit

April 4, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Safety of Device

    Occurrence of device-related adverse events.

    6 weeks

Secondary Outcomes (2)

  • Label Comprehension Assessment Protocol

    6 weeks

  • Device Usability

    6 weeks

Study Arms (1)

Study Population

Up to 20 subjects will be recruited from the patient population at the Principal Investigator's clinic. Subject recruitment will end once 15 evaluable subjects have completed the study.

Device: FERTI LILY Conception Cup

Interventions

The FERTI-LILY Conception Cup is indicated for over-the-counter (OTC) home use by couples trying to conceive. The FERTI·LILY device OTC contains a cervical cap attached to a stem. The FERTI-LILY Conception Cup is intended to push semen towards the cervix as an aid in conception. It is designed to be inserted vaginally after intercourse and left in place for 20-60 minutes. The device is recommended to be used during the ovulatory phase of the menstrual cycle. It is not to be left in place for longer than six hours. The device may be re-used up to 18 times or over 6 cycles.

Study Population

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsSubject is a female volunteer, age ≥ 18 years.
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects who meet study eligibility criteria will be recruited from the patient population of the Principle Investigator's clinic.

You may qualify if:

  • Subject is a female volunteer, age ≥ 18 years.
  • Subject is willing and able to provide written informed consent for study participation.
  • Subject agrees to use the FCC device as directed.
  • Subject agrees to complete all study-related assessments.
  • Subject agrees to try to use the cup within two weeks of disposition.
  • PI confirms that the subject had the adequate label comprehension to enroll in the study.

You may not qualify if:

  • Subject has a medical condition or other factor that, in the opinion of the investigator, would contraindicate participation in the study.
  • Subject has active bacterial vaginosis infection or vaginismus.
  • Subject has an abnormal clinically significant Pap Smear diagnosis.
  • Subject has a history of endometriosis.
  • Subject has any contraindications with the Instructions for Use.
  • Subject has an allergy to silicone.
  • Subject is pregnant or lactating.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Boca Raton Obstetrics and Gynecology

Boca Raton, Florida, 33431, United States

Location

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 1, 2022

First Posted

September 6, 2022

Study Start

July 29, 2022

Primary Completion

September 20, 2022

Study Completion

September 21, 2022

Last Updated

April 6, 2023

Record last verified: 2022-09

Locations